Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how they plan to formally engage with the wider health sector and industry partners on the next stages in the development of proposed changes to Part IX of the Drug Tariff, following the conclusion of the consultation on these proposals.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The consultation response on the proposed amendments to Part IX and the final impact assessment is expected to be released in May 2024, and will outline the Government’s response.
The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers.
These proposals support the Life Sciences Vision, and are designed to increase innovation and alignment between partners in the health and care system. The enhanced assessment process will allow comparison between products based on their merits, increasing transparency and competition, and encouraging new products and small and medium sized businesses to enter the market. The proposed introduction of environmental attributes in social value scoring increases the vision to help the National Health Service meet Net Zero.
The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and NHS organisations. The Department will share a timeline of proposed changes taken forward, in due course.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what consideration was given to the costs of complicated grief in families of patients dying from SOD-1 MND during the evaluation process that led to the decision to decline access to tofersen for NHS patients.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the negative impact on pharmaceutical research investment in the UK of the refusal by National Institute for Health and Care Excellence to approve tofersen for SOD-1 MND patients in the UK.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not yet started its evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations, and has therefore not published any guidance or recommendations on whether tofersen should be available for National Health Service patients. In developing its recommendations, the NICE will follow its published methods for health technology evaluation, which will include a thorough assessment of the available evidence. This takes into account all health-related costs and benefits, including health benefits not only to patients but, where relevant, to other people such as carers. The NICE’s aim is to publish its guidance on tofersen as close as possible to the date it receives its marketing authorisation.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions her Department has had with the Department for Science, Innovation and Technology on funding for (a) the Lobular Moon Shot Project and (b) other research into lobular breast cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and the Medical Research Council (MRC), who are responsible for channelling a large proportion of the Department for Science, Innovation and Technology’s investments in this area. Our officials meet regularly to discuss a wide range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. While research to understand the mechanisms of cancer, including lobular breast cancer, is largely funded through UKRI and the MRC, the NIHR invests in translational and implementation research to drive innovations into policy and practice.
Launched in 2023, the Lobular Moonshot Project is a high-level funding proposal and campaign to raise money to support the Institute for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and projects in lobular breast cancer. We are proud to have invested £29 million in the ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, again including lobular breast cancer. This is complemented by wider investments into breast cancer research, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, such as lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.
Additionally, the NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years, the CRN has supported delivery of 10 lobular breast cancer-related studies conducted by other partners. While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and care, which saves lives.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to provide support to the Lobular Breast Cancer Project.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests £1.3 billion per year into health research, with more spent on cancer than any other disease group, through the National Institute for Health and Care Research (NIHR). We work closely with UK Research and Innovation (UKRI) and the Medical Research Council (MRC), who are responsible for channelling a large proportion of the Department for Science, Innovation and Technology’s investments in this area. Our officials meet regularly to discuss a wide range of our investments, including into lobular and other breast cancers, to drive the maximum collective research impact on policy, practice, and individual lives. While research to understand the mechanisms of cancer, including lobular breast cancer, is largely funded through UKRI and the MRC, the NIHR invests in translational and implementation research to drive innovations into policy and practice.
Launched in 2023, the Lobular Moonshot Project is a high-level funding proposal and campaign to raise money to support the Institute for Cancer Research (ICR), with whom we meet regularly, to invest in fellowships and projects in lobular breast cancer. We are proud to have invested £29 million in the ICR and Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, again including lobular breast cancer. This is complemented by wider investments into breast cancer research, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, such as lobular breast cancer. Our support to the NIHR Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer related studies.
Additionally, the NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years, the CRN has supported delivery of 10 lobular breast cancer-related studies conducted by other partners. While the NIHR cannot respond to direct solicitations for funding, instead commissioning on the basis of research excellence, we would welcome more applications from researchers on lobular breast cancer, including from the ICR. The NIHR funds research on cancer prevention, detection, diagnosis, treatment, and care, which saves lives.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the public's awareness of the side effects that can arise from taking weight loss drugs such as Ozempic.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) plays a pivotal role in ensuring the safety, efficacy, and quality of medicines and healthcare products available to patients in the United Kingdom. Patient safety remains the MHRA’s highest priority, and they take every opportunity to encourage reporting of any safety concerns to the Yellow Card scheme, which helps to improve the safe use of medicines and medical devices for everyone.
New medicines including, Mounjaro and Wegovy, are intensively monitored to ensure that any new safety concerns are identified promptly. The Commission on Human Medicines and the MHRA encourages the reporting of all suspected reactions to newer drugs and vaccines, which are denoted by an inverted Black Triangle symbol. This symbol appears next to the name of a relevant product in drug safety updates, the British National Formulary and the Nurse Prescribers’ Formulary, the monthly index of medical specialities, the electronic medicines compendium, and advertising material. Patient information leaflets accompanying licensed medicines in the UK must include a description of the adverse reactions which may occur in normal use of the medicinal product, as well as information on how to report them. All adverse reactions must be reflected in the leaflet, in language that the patient will understand.
The MHRA has received a small number of reports of falsified and unlicenced medicines being sold illegally online as a treatment for weight loss. The agency has issued public health messaging warning of the dangers of buying such medicines from illegal trading sources online.
Asked by: Geoffrey Cox (Conservative - Torridge and West Devon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help tackle (a) sexism, (b) racism and (c) bullying behaviour within the ambulance service; and if she will establish an independent body to review complaints made by ambulance workers.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Everyone working in the National Health Service must feel safe from any form of bullying, harassment, discrimination, or abuse, and feel confident that they can raise concerns, which will be taken seriously and acted on.
The Department welcomes the publication of the NHS England commissioned independent review into ambulance sector culture. NHS England has established a Delivery Board to deliver the review’s important recommendations. This includes actions led by the Office of the Chief Allied Health Professions at NHS England, and the Association of Ambulance Chief Executives, on stopping misogyny and improving sexual safety in the ambulance service. This programme of work will build on the work already underway through the NHS People Plan, and the Equality, Diversity and Inclusion Improvement Plan
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the implications for her policies of the prices available to (a) large companies and (b) independent pharmacies for the purchase of pharmaceuticals from wholesalers.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed, as part of the community pharmacy contractual framework. The medicine margin survey considers what a sample of independent pharmacies paid, by looking at their invoices compared to the amount reimbursed by the National Health Service. As large companies are considered to have greater buying power, they are not sampled in the medicine margin survey.
Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, it is known as a concessionary price.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of a rebate scheme for the cost of pharmaceuticals for community pharmacies.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Community pharmacies are responsible for purchasing the medicines and other products that they supply as part of National Health Service pharmaceutical services. The purchase price, including rebates schemes available to them, is a commercial decision for the pharmaceutical wholesalers and manufacturers who sell to them.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve access to breast screening for people with physical disabilities that prevent them from holding the required position for sufficient time to complete the screening.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is committed to improving the accessibility of the screening programmes it commissions under the Public Health Services (S7a) agreement, particularly for under-served groups in society. Contractually, providers of National Health Service screening services are required to make reasonable adjustments to ensure that their services are accessible for people with disabilities. For example, the NHS breast screening service offers longer appointments at accessible sites to support women with physical disabilities.
Services make reasonable adjustments within the constraints of mammography equipment, to ensure that people with disabilities are offered the opportunity to have screening. However, there may be situations where this is not possible. Providers will deal with these on a case by case basis, and offer an alternative approach as necessary. For example, for women who are unable to have a mammogram, they may be offered a referral to a symptomatic breast clinic for a physical check.